The field of CNS tumor genomics has seen significant advancements aimed at improving diagnostic accuracy and speed. A notable study introduced MethyLYZR, a naive Bayesian framework that allows for rapid classification of brain tumors based on sparse epigenomic data. This method addresses the longstanding challenge of achieving intraoperative molecular diagnosis within a clinically relevant timeframe, specifically under one hour post-biopsy. The study highlights that while traditional machine learning techniques are computationally intensive and impractical for real-time clinical applications, MethyLYZR offers a tractable solution that could revolutionize live diagnostic workflows (ref: Brändl doi.org/10.1038/s41591-024-03435-3/). Furthermore, research on RBM10 deficiency has uncovered its role in promoting brain metastasis in patients with EGFR-mutated lung adenocarcinoma. This study elucidates the mechanism by which RBM10 modulates sphingolipid metabolism, thereby inhibiting brain metastasis, which is crucial for understanding therapeutic failures in this patient population (ref: Xu doi.org/10.1186/s13046-025-03347-1/). Together, these findings underscore the importance of molecular diagnostics and the need for targeted therapies in managing CNS tumors and their metastases.